[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrentmetastatic-breast-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrentmetastatic-breast-cancer":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100196980","breast-cancer-proteomics-and-molecular-heterogeneity-100196980",false,"NCT01840293","Breast Cancer Proteomics and Molecular Heterogeneity","Inclusion Criteria:\n\n1. Patients diagnosed with primary breast cancer attending hospital for the resection of their tumour tissue\n\n   Or\n\n   -Patients with suspected or confirmed recurrent or metastatic breast cancer (Patient has a history of a biopsy- or surgically- (i.e. pathologically) confirmed primary breast cancer) attending hospital for the resection\u002Fbiopsy and\u002For treatment of tumour tissue\n\n   Or\n\n   -Patient with suspected (but not necessarily biopsy confirmed) newly diagnosed stage 4 breast cancer attending hospital for the resection\u002Fbiopsy and\u002For treatment of their tumour tissue\n2. Patients receiving neoadjuvant treatment are also eligible (if applicable)\n3. Patients have to be ≥ 18 years of age\n4. Patients must be able to give informed consent","FEMALE","18 Years",{"count":18,"type":19},1780,"ESTIMATED","OBSERVATIONAL","Primary objective:\n\nThe primary objective is to define the proteomic and molecular characteristics of primary and recurrent\u002F metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) genes\n\nSecondary objective:\n\n* To expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes.\n* To relate proteomic findings to survival data\n* To identify potential serum markers of breast cancer progression",[23,24],"Primary Breast Cancer","Recurrent\u002FMetastatic Breast Cancer","RECRUITING","2025-12-15",{"date":28,"type":29},"2025-12-19","ACTUAL",{"date":31,"type":29},"2013-02",{"date":33,"type":19},"2038-01",{"name":35,"class":36},"Cancer Trials Ireland","NETWORK",6]